Literature DB >> 25123037

IGFBP1 in epithelial circulating tumor cells as a potential response marker to selective internal radiation therapy in hepatocellular carcinoma.

Ivonne Nel1, Hideo A Baba, Frank Weber, Barbara Sitek, Martin Eisenacher, Helmut E Meyer, Joerg F Schlaak, Andreas-Claudius Hoffmann.   

Abstract

BACKGROUND: Local ablative techniques such as selective internal radiation therapy (SIRT) have become the mainstay of treating hepatocellular carcinoma (HCC) in the bridging-to-transplant and palliative setting. We recently demonstrated that epithelial circulating tumor cells (CTCs) correlate to an unfavorable outcome. We wanted to scrutinize whether molecular markers detected in this specific CTC subgroup may also have clinical implications. MATERIALS &
METHODS: Mononuclear cells and CTCs were isolated from peripheral blood samples using density gradient centrifugation followed by depletion of hematopoietic and enrichment of epithelial (EpCAM(+)) cells employing immunomagnetic beads. The mRNA expression of candidate markers was correlated with response to SIRT in 25 patients using quantitative real-time reverse-transcription PCR.
RESULTS: IGFBP1 mRNA expression levels were significantly correlated with time to progression in a Kaplan-Meier log rank test (p = 0.04; 0 vs 4 months) and receiver operating characteristic analysis demonstrated a potential use to predict patients with shortened time to progression (area under the curve: 0.8; 95% CI: 0.44-0.98; p = 0.03).
CONCLUSION: The EpCAM fraction of CTCs may be useful to detect novel molecular markers to individualize treatment decision in patients with HCC.

Entities:  

Keywords:  AFP; EpCAM; IGFBP1; SIRT; circulating tumor cells; epithelial cells; hepatocellular carcinoma; peripheral blood

Mesh:

Substances:

Year:  2014        PMID: 25123037     DOI: 10.2217/bmm.14.23

Source DB:  PubMed          Journal:  Biomark Med        ISSN: 1752-0363            Impact factor:   2.851


  7 in total

Review 1.  IGFBP-1 in cancer: expression, molecular mechanisms, and potential clinical implications.

Authors:  Yi-Wei Lin; Xue-Fen Weng; Bin-Liang Huang; Hai-Peng Guo; Yi-Wei Xu; Yu-Hui Peng
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

2.  Circulating Tumor Cell Composition in Renal Cell Carcinoma.

Authors:  Ivonne Nel; Thomas C Gauler; Kira Bublitz; Lazaros Lazaridis; André Goergens; Bernd Giebel; Martin Schuler; Andreas-Claudius Hoffmann
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240

Review 3.  The Significance of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma: Real-Time Monitoring and Moving Targets for Cancer Therapy.

Authors:  Feiyu Chen; Zhangfeng Zhong; Hor-Yue Tan; Ning Wang; Yibin Feng
Journal:  Cancers (Basel)       Date:  2020-06-29       Impact factor: 6.639

4.  The clinical significance of CTC enrichment by GPC3-IML and its genetic analysis in hepatocellular carcinoma.

Authors:  Bin Yi; Tian Wu; Nan Zhu; Yao Huang; Xiaoyu Yang; Lei Yuan; Yingjun Wu; Xiaofei Liang; Xiaoqing Jiang
Journal:  J Nanobiotechnology       Date:  2021-03-16       Impact factor: 10.435

Review 5.  Liquid Biopsy in Hepatocellular Carcinoma: Where Are We Now?

Authors:  Filippo Pelizzaro; Romilda Cardin; Barbara Penzo; Elisa Pinto; Alessandro Vitale; Umberto Cillo; Francesco Paolo Russo; Fabio Farinati
Journal:  Cancers (Basel)       Date:  2021-05-10       Impact factor: 6.639

6.  Inter-regulation of IGFBP1 and FOXO3a unveils novel mechanism in ursolic acid-inhibited growth of hepatocellular carcinoma cells.

Authors:  Li Jun Yang; Qing Tang; Jingjing Wu; Yuqing Chen; Fang Zheng; Zhenhui Dai; Swei Sunny Hann
Journal:  J Exp Clin Cancer Res       Date:  2016-03-31

7.  Circulating tumor cells and CXCR4 in the prognosis of hepatocellular carcinoma.

Authors:  Tao Bai; Rongyun Mai; Jiazhou Ye; Jie Chen; Lunan Qi; Juan Tang; Meng Wei; Lianda Zhang; Zhiwei Chen; Zhihong Tang; Lequn Li; Feixiang Wu
Journal:  Transl Cancer Res       Date:  2020-03       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.